» Articles » PMID: 1578946

Longterm Effects of Prolonged Maintenance and of Very Early Intensification Chemotherapy in AML: Data from AMLCG

Overview
Journal Leukemia
Specialties Hematology
Oncology
Date 1992 Jan 1
PMID 1578946
Citations 3
Authors
Affiliations
Soon will be listed here.
Abstract

In order to further improve the cure rate in AML we investigated the effect of more chemotherapy--in terms of its intensity and its duration--in 2 studies. In our 1981 study patients received TAD 1-2 courses for induction, 1 course for consolidation and randomly no further treatment or monthly myelosuppressive maintenance for 3 years. Evaluating 213 responders remission duration was clearly longer in the maintenance group with 24% CCR after 5 and 10 years. In our 1985 study the same successful strategy was further intensified by a second induction course given regardless of response to the first course to all patients up to 60 years of age while older patients received standard induction as before. This age-adapted concept resulted in a further increase of 5 years CCR in the 461 responders to as much as 34% not achieved for unselected patients in other multicenter trials. 20 patients receiving auto-BMT in first CR show the same relapse free survival as their counterparts receiving chemotherapy according to the 1985 protocol in a matched-pair analysis. We conclude that both very early intensification and prolonged maintenance contribute to a higher cure rate that is not further improved even by a maximum intensity short-term treatment. The limits of chemotherapy in AML may be overcome by modulating its myelotoxicity and antileukemic potency using GM-CSF as shown in 2 studies of our group.

Citing Articles

Maintenance Therapy in AML.

Reville P, Kadia T Front Oncol. 2021; 10:619085.

PMID: 33604298 PMC: 7884813. DOI: 10.3389/fonc.2020.619085.


Maintenance therapy in acute myeloid leukemia: an evidence-based review of randomized trials.

Rashidi A, Walter R, Tallman M, Appelbaum F, Dipersio J Blood. 2016; 128(6):763-73.

PMID: 27354720 PMC: 4982451. DOI: 10.1182/blood-2016-03-674127.


Optimal therapy for adult patients with acute myeloid leukemia in first complete remission.

Wiernik P Curr Treat Options Oncol. 2014; 15(2):171-86.

PMID: 24792016 DOI: 10.1007/s11864-014-0281-9.